BANCOLOMBIA S.A. TO DELIST NOTES FROM THE NEW YORK STOCK EXCHANGE
Codexis (NASDAQ: CDXS), a provider of enzymatic solutions for therapeutics manufacturing, has announced its participation in the upcoming Jefferies Global Healthcare Conference. The event will take place from June 3-5, 2025 in New York.
The company's management will engage in a fireside chat on June 4, 2025, at 3:10 pm ET. Investors can access a live webcast of the presentation through Codexis's investor relations website, with a replay available for 90 days after the event.
Codexis (NASDAQ: CDXS), fornitore di soluzioni enzimatiche per la produzione di terapie, ha annunciato la sua partecipazione alla prossima Jefferies Global Healthcare Conference. L'evento si svolger脿 dal 3 al 5 giugno 2025 a New York.
La direzione dell'azienda parteciper脿 a un incontro informale il 4 giugno 2025 alle 15:10 ET. Gli investitori potranno seguire la presentazione in diretta streaming tramite il sito web delle relazioni con gli investitori di Codexis, con una replica disponibile per 90 giorni dopo l'evento.
Codexis (NASDAQ: CDXS), proveedor de soluciones enzim谩ticas para la fabricaci贸n de terapias, ha anunciado su participaci贸n en la pr贸xima Conferencia Global de Salud de Jefferies. El evento se llevar谩 a cabo del 3 al 5 de junio de 2025 en Nueva York.
La direcci贸n de la empresa participar谩 en una charla informal el 4 de junio de 2025 a las 3:10 pm ET. Los inversores podr谩n acceder a una transmisi贸n en vivo de la presentaci贸n a trav茅s del sitio web de relaciones con inversores de Codexis, con una repetici贸n disponible durante 90 d铆as despu茅s del evento.
Codexis (NASDAQ: CDXS)電� 旃橂鞝� 鞝滌“毳� 鞙勴暅 須唽 靻旊（靺� 鞝滉车鞐呾泊搿滌劀 雼り皜鞓る姅 Jefferies 旮�搿滊矊 項姢旒�鞏� 旎嵓霟办姢鞐� 彀胳棳頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟. 頄夓偓電� 2025雲� 6鞗� 3鞚茧秬韯� 5鞚缄箤歆� 雺挫殨鞐愳劀 臧滌禍霅╇媹雼�.
須岇偓 瓴届榿歆勳潃 2025雲� 6鞗� 4鞚� 鞓ろ泟 3鞁� 10攵�(霃欕秬鞁滉皠)鞐� 韺岇澊鞏挫偓鞚措摐 毂勴寘鞐� 彀胳棳頃� 鞓堨爼鞛呺媹雼�. 韴瀽鞛愲摛鞚� Codexis 韴瀽鞛� 甏�瓿� 鞗轨偓鞚错姼毳� 韱淀暣 靸濎瓿� 鞁滌箔鞚� 臧�電ロ晿氅�, 頄夓偓 頉� 90鞚缄皠 雼れ嫓氤搓赴 靹滊箘鞀る弰 鞝滉车霅╇媹雼�.
Codexis (NASDAQ : CDXS), fournisseur de solutions enzymatiques pour la fabrication de produits th茅rapeutiques, a annonc茅 sa participation 脿 la prochaine conf茅rence mondiale Jefferies Global Healthcare. L'茅v茅nement aura lieu du 3 au 5 juin 2025 脿 New York.
La direction de l'entreprise participera 脿 une discussion informelle le 4 juin 2025 脿 15h10 ET. Les investisseurs pourront acc茅der 脿 une diffusion en direct de la pr茅sentation via le site des relations investisseurs de Codexis, avec un replay disponible pendant 90 jours apr猫s l'茅v茅nement.
Codexis (NASDAQ: CDXS), ein Anbieter enzymatischer L枚sungen f眉r die Herstellung von Therapeutika, hat seine Teilnahme an der bevorstehenden Jefferies Global Healthcare Conference angek眉ndigt. Die Veranstaltung findet vom 3. bis 5. Juni 2025 in New York statt.
Das Management des Unternehmens wird am 4. Juni 2025 um 15:10 Uhr ET an einem Fireside-Chat teilnehmen. Investoren k枚nnen die Pr盲sentation live 眉ber die Investor-Relations-Website von Codexis verfolgen, eine Aufzeichnung steht f眉r 90 Tage nach der Veranstaltung zur Verf眉gung.
- None.
- None.
REDWOOD CITY, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS),聽a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the Company will attend the Jefferies Global Healthcare Conference, being held June 3-5, 2025, in New York, New York.
Management will participate in a fireside chat on Wednesday, June 4, 2025, at 3:10 pm ET. A live webcast of the event will be available in the Investor Relations section of the Company鈥檚 website,聽. A replay will be archived for 90 days following the event.
About Codexis
Codexis is a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, leveraging its proprietary CodeEvolver庐聽technology platform to discover, develop and enhance novel, high-performance enzymes. Codexis enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis鈩� manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis鈥� unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. For more information, visit聽.
For More Information
Investor Contact
Carrie McKim
(336) 608-9706
FAQ
When is Codexis (CDXS) presenting at the Jefferies Global Healthcare Conference 2025?
Where can I watch Codexis's (CDXS) Jefferies Conference presentation?
How long will the replay of Codexis's (CDXS) Jefferies Conference presentation be available?
What is the date of the 2025 Jefferies Global Healthcare Conference?
